Canada markets closed

Atai Life Sciences N.V. (ATAI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.7900-0.0300 (-1.65%)
At close: 04:00PM EST
1.7900 0.00 (0.00%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close1.8200
Open1.8100
Bid1.7800 x 2200
Ask1.7900 x 1400
Day's Range1.7700 - 1.8400
52 Week Range1.4500 - 6.3200
Volume1,213,767
Avg. Volume1,479,988
Market Cap296.916M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.3990
Earnings DateNov 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.58
  • News Direct

    Trippy Trading: Top Psychedelic Stocks For 2023

    When psychedelics were first studied more than 50 years ago, researchers discovered that they were useful in assisting people in exploring a greater sense of self. After a half-century hiatus, scie...

  • Market Exclusive

    Weekly Roundup on the Cannabis Sector & Psychedelic Sector

    Key Takeaways; Cannabis Sector Leafly Holdings started the year with strong market performance. Innovative Industrial Properties’ market performance remained robust, following the announcement of significant dividends for 2022. Columbia Care subsidiary is carrying out large-scale cannabis industry layoffs. Key Takeaways; Psychedelic Sector Awakn’s ketamine-assisted psychotherapy for the treatment of AUD was ranked as the 5th […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector

  • GlobeNewswire

    atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917

    GRX-917 (deuterated etifoxine) was well-tolerated with no dose-limiting toxicities and only mild adverse effects comparable to that of placebo in both single and multiple ascending doses, as previously announced as preliminary results during atai’s R&D day.Final results demonstrate target engagement of GRX-917 via dose-related activation of quantitative electroencephalography (qEEG) frontal beta power, a biomarker for GABA-A receptor-associated anxiolytic activity, consistent with GRX-917’s puta